8-KEarnings & ResultsMaterial AgreementsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Feb 23, 2005)

Filed February 23, 2005For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 23, 2005, detailing two key events. Firstly, the company entered into Amendment No. 5 to its Manufacturing Agreement with Merck & Co., Inc. This amendment extends the agreement, under which Regeneron produces an intermediate for a Merck pediatric vaccine, through October 31, 2006, with an option for Merck to extend for another year. This extension provides continued revenue visibility from this partnership. Secondly, the filing includes a press release announcing Regeneron's financial and operating results for the quarter and year ended December 31, 2004. While the specifics of these results are not detailed within the 8-K text itself, their inclusion signifies a material update for investors regarding the company's performance and financial condition as of the end of 2004.

Key Highlights

  • 1Regeneron and Merck & Co., Inc. amended their Manufacturing Agreement, extending production of a pediatric vaccine intermediate.
  • 2The manufacturing agreement is extended through October 31, 2006, with an option for Merck to extend through October 31, 2007.
  • 3The amendment became effective as of January 1, 2005.
  • 4Regeneron produces the vaccine intermediate at its Rensselaer, New York facility.
  • 5The 8-K includes a press release detailing Regeneron's financial and operating results for the year and quarter ended December 31, 2004.
  • 6The press release is furnished as an exhibit and not considered 'filed' for most SEC purposes.

Frequently Asked Questions

The primary impact is the extension of a revenue-generating contract with Merck through at least October 31, 2006, providing greater financial predictability for Regeneron from this specific agreement. It also includes an option for a further one-year extension.

Regeneron manufactures an intermediate for a Merck pediatric vaccine.

The manufacturing is being conducted at Regeneron's facility located in Rensselaer, New York.

This 8-K filing announces that Regeneron released its financial and operating results for the period. The detailed results are provided in an attached press release (Exhibit 99(a)), which is furnished as part of the filing.